Research synthesisLow evidenceMixed effect size4 studies · 2 beneficial · 2 neutral · 0 harmful
Across 4 studies, 2 reported beneficial effects of N-Acetyl Cysteine on platelet recovery, with large and moderate effect sizes observed in critically ill adults and HSCT patients, respectively. The remaining 2 studies found neutral effects in thrombocytopenic populations, and the median study duration was 365 days (based on 1 study). The most-studied dose was 600 mg every 12 hours, though dosing varied widely across studies.
- Effective dose range: 400-600 mg every 8-12 h
- Studied populations: critically ill adults receiving linezolid, myeloid malignancies patients undergoing hematopoietic stem cell transplant (HSCT)
Caveats: Evidence base is small (only 4 studies) — conclusions should be considered preliminary. Many of the included studies did not reach statistical significance (only 2 of 4 reported significant findings) — effect may be smaller than the predominant direction suggests. The two beneficial studies used NAC in specific clinical settings (linezolid-associated thrombocytopenia and conditioning therapy for HSCT), which may limit generalizability to other thrombocytopenic populations. Two neutral studies examined immune thrombocytopenia and thrombotic thrombocytopenic purpura, suggesting benefit may be context-dependent.
Generated May 13, 2026